Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. […]
Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients
Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai platform accurately analyzed and classified the spatial arrangement of immune cells in the tumor microenvironment (TME) to identify metastatic non-small cell lung cancer (mNSCLC) patients […]
Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets
Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced the appointment of Kenneth J. Bloom, MD, FCAP as the company’s new head of pathology. Dr. Bloom brings more than 35 years of clinical experience in pathology, oncology, telemedicine and bioinformatics to this critical role at […]
Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors
Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s […]
Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images
Nucleai, a leader in Artificial Intelligence (AI) powered spatial analysis for pathology, and Ultivue, an industry leader in multiplexing tools for tissue biomarker studies, today announced a collaboration to advance the discovery of novel spatial biomarkers. The partnership will layer Nucleai’s cutting-edge AI spatial models on top of Ultivue’s imaging technology to unlock the complex […]
Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin’s Lymphoma (Newsw
Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, today announced that it will share new data at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in an online publication on an exploratory analysis of a phase 2 […]
Top 10 Spatial Biology Companies for 2022 [GenEngNews]
Spatial biology is among the smaller segments of the broader life sciences market. One estimate issued in August by Research And Markets, has the market growing from 2021-2028 at a 10% compound annual growth rate $484.22 million, which would put its value this year at just under $250 million. The field made its way into the […]
Nucleai Raises $33M in Series B Round [GenomeWeb]
Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday. Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations. The company’s platform helps […]
Nucleai Announces $33 Million Series B Funding from Section 32 and Sanofi Ventures
Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics. Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform.
Nucleai and Jefferson Health Launch a Strategic Collaboration to Discover Novel Spatial Immunotherapy Biomarkers Utilizing Nucleai’s Spatial Biology Platform
Nucleai, a leader in AI-powered spatial biology, and Jefferson Health, a leading cancer center, announce that they have entered into a strategic collaboration to discover spatial immunotherapy biomarkers, leveraging Nucleai’s ATOM platform and Jefferson’s repository of pathology and clinical data.
